Close
What would you like to look for?
Search filters

Novaremed and NeuroFront enter option and license agreement for NRD.E1

25 July 2022

Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.

VISCHER advises e-hoi AG on the acquisition of Cruise Center AG

19 July 2022

Cruise Center AG, a Swiss company that has been selling cruises for over twenty years, was acquired by the cruise agency e-hoi with retroactive effect from 1 January 2022.

ImmunOs Therapeutics AG to raise CHF 74m Series B financing

7 June 2022

ImmunOs Therapeutics AG has agreed to a CHF 74 million Series B financing led by incoming co-lead investors Samsara Biocapital, Lightspeed Venture Partners and Gimv, corner-stoned by GL Capital, Mission BioCapital, Peak 6 Strategic Capital and Fiscus Financial

Andean Telecom Partners acquires BTS Towers

15 March 2022

Andean Telecom Partners ("ATP"), a leading owner and operator of telecommunications infrastructure in the Andean Region, acquired BTS Towers ("BTS"), a privately owned provider of telecommunications infrastructure, headquartered...

VISCHER advises on MBO of Ulysse Nardin & Girard-Perregaux

22 February 2022

On January 24, 2022, Kering entered into an agreement for the sale of its entire stake (100%) in Sowind Group SA, which owns the Swiss watch manufacturers Girard-Perregaux and Ulysse Nardin, to its current management.

VISCHER...

Gilde Buy Out Partners joins forces with Founders and Management of MBK

15 February 2022

Funds advised by Gilde Buy Out Partners, a leading European private equity investor, completed the investment in MBK Fincom ("MBK" or the "Company"), alongside the founders and management which are reinvesting in the business....

NEMIS Technologies AG closed a CHF 7.75m Series A Financing Round

10 February 2022

NEMIS Technologies AG closed a CHF 7.75m Series A financing round with the participation of both institutional and private investors.

Rigeto Investors acquired Laser Beauté Med SA

10 January 2022

A group of investors advised by Rigeto Unternehmerkapital GmbH has acquired 100% of the shares in Laser Beauté Med SA, headquartered in Sion with additional locations in Monthey and Visp.

Sale of deepCDR Biologics AG to Alloy Therapeutics Inc.

20 December 2021

deepCDR Biologics AG, ein in Basel ansässiges Start-Up, das sich auf die Entdeckung und Entwicklung von Antikörpern spezialisiert hat, wurde von Alloy Therapeutics Inc., ein in Boston ansässiges Biotechnologieunternehmen, übernommen.

Orell Füssli Thalia AG acquires a stake in Evrlearn AG

10 December 2021

Orell Füssli Thalia AG acquired a stake as Lead Investor in the digital community platform Evrlearn AG.